Contact

  • English
  • Español
  • Analysis

    Policy Brief n°8: How investing today can reduce the need for aid tomorrow: health as a case study

    Publié le 08/05/2021.

    Official development assistance (ODA) is regularly criticised for being unnecessary, or ineffective. However, when it comes to addressing health challenges in developing countries, there is widespread support for the provision of funding to the poorest.

    In this way, the perception of effectiveness or “value for money” can be correlated to certain sectors where ODA is seen as a worthwhile investment now, to reduce further spending in the future. This is the case for global health aid, which is one of the best possible investments in terms of a cost-benefit assessment.

    According to the experts of The Lancet’s “Investing in Health” commission, every dollar invested generates an economic return of of 9-20 dollars in developing and middle-income countries.

    An excellent example is the fall in costs for vaccinations thanks to donor investment in a new global vaccine initiative, GAVI.

    The same is true of global pandemics, where investing now in prevention and treatment of diseases (such as HIV) can help avoid much higher human and economic costs further down the line. Or polio: according to figures from the Global Polio Eradication Initiative (GPEI), completely eradicating polio would save between 40 and 50 billion USD in health costs and from loss of productivity. And yet, according to the World Health Organisation, a lack of political will for a final push might mean that the few dozen remaining cases of polio a year could rise to 200,000 annually within the next ten years.

    You can download the Policy Brief n°8 in French here. An English translation is forthcoming.

    Pour aller plus loin
  • Note d’analyse n°8 : Investir dans l’aide publique au développement pour réduire les dépenses à venir, l’exemple de l’aide en santé
  • À LIRE AUSSI

    - 22 October 2024

    France’s Official Development Assistance in a world of uncertainty: a fading ambition? Review 2017-2024 and outlook

    Where do we stand on the evolution of France's ODA policy since 2017? With figures to back it up, Focus 2030 takes a closer look, at a time when France's ambitions may be coming to an end.
    Sustainable Development Goals - 17 June 2024

    Replenishment of Gavi, the Vaccine Alliance: Vaccinating half of the world’s children

    Gavi, the Vaccine Alliance, intends to mobilize funding for its 2026-2030 strategy. In this special report, you'll find the latest news, facts and figures, campaigns and interviews with experts.
    - 07 May 2024

    Which countries fund global health?

    Focus 2030 analyses the funding promoting access to health in developing countries by industrialised countries, particularly France.
    - 27 July 2023

    Global health: what will be the international milestones in 2023?

    April 7, 2023 marks World Health Day and the 75th anniversary of the WHO. This is an opportunity to take stock of some major news in global health: high-level UN meetings on universal health coverage, pandemic preparedness and the fight against tuberculosis, the Summit for a new global financing pact, the Gavi global conference on immunization, the eradication of polio...
    - 25 May 2022

    International solidarity and France’s role in the world: prospects for the new government

    Overview of the major international conferences of the next five years and the issues that France will have to tackle to contribute to the achievement of the SDGs.
    - 04 April 2022

    Assessment of France’s international development policy during Emmanuel Macron’s five-year term

    How has France's development and international solidarity policy fared during the last five years? Analysis.
    X

    Formulaire d'abonnement à la newsletter de Focus2030

    * indicates required

    Focus 2030 vous transmettra sa newsletter sur l'email fourni dans ce formulaire.

    Je comprends que je peux me désabonner facilement à tout moment en cliquant sur le lien en bas de page de nos lettres d'information. Vos données personnelles collectées resteront strictement confidentielles. Elles ne seront ni vendues ni échangées conformément à nos mentions légales. Pour plus d'informations sur notre politique de confidentialité, consultez notre site web.

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.